Identificare marker biochimici di eccesso di cortisolo che predicono possibili danni d’organo
Valutare mediante l’utilizzo della spettrometria di massa per la misura dei metaboliti intermedi se nel tempo alcuni adenomi surrenalici non funzionanti acquisiscono capacità secernenti
Poter identificare la classe di pazienti a maggior rischio evolutivo
Poter definire con certezza il tipo di trattamento ottimale se conservativo o chirurgico Definire i costi effettivi dei protocolli di follow up, l’utilità e la necessità
60
BIBLIOGRAFIA
1. Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European
Network for the Study of Adrenal Tumors. European journal of endocrinology 2016; 175(2): G1- g34.
2. Favia G, Lumachi F, Basso S, D'Amico DF. Management of incidentally discovered adrenal masses and risk of malignancy. Surgery 2000; 128(6): 918-24.
3. Araujo-Castro M, Sampedro Nunez MA, Marazuela M. Autonomous cortisol secretion in adrenal incidentalomas. Endocrine 2019; 64(1): 1-13.
4. Grumbach MM, Biller BMK, Braunstein GD, et al. Management of the clinically inapparent adrenal mass ("incidentaloma"). Annals of Internal Medicine 2003; 138(5): 424-9. 5. Herrera MF, Grant CS, van Heerden JA, Sheedy Ii PF, Iistrup DM. Incidentally
discovered adrenal tumors: An institutional perspective. Surgery 1991; 110(6): 1014-21. 6. Bovio S, Cataldi A, Reimondo G, et al. Prevalence of adrenal incidentaloma in a contemporary computerized tomography series. Journal of endocrinological investigation 2006; 29(4): 298-302.
7. Barzon L, Sonino N, Fallo F, Palù G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. European journal of endocrinology 2003; 149(4): 273-85.
8. Young WF, Jr. Clinical practice. The incidentally discovered adrenal mass. The New
England journal of medicine 2007; 356(6): 601-10.
9. Kloos RT, Gross MD, Francis IR, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocrine reviews 1995; 16(4): 460-84.
10. Aron DC. The adrenal incidentaloma: disease of modern technology and public health problem. Reviews in endocrine & metabolic disorders 2001; 2(3): 335-42.
11. Mantero F, Albiger N. A comprehensive approach to adrenal incidentalomas. Arquivos
brasileiros de endocrinologia e metabologia 2004; 48(5): 583-91.
12. Mayer SK, Oligny LL, Deal C, Yazbeck S, Gagne N, Blanchard H. Childhood adrenocortical tumors: case series and reevaluation of prognosis--a 24-year experience.
Journal of pediatric surgery 1997; 32(6): 911-5.
13. Debono M, Newell-Price J. Subclinical hypercortisolism in adrenal incidentaloma.
Current opinion in endocrinology, diabetes, and obesity 2015; 22(3): 185-92.
14. Androulakis, II, Kaltsas G, Piaditis G, Grossman AB. The clinical significance of adrenal incidentalomas. European journal of clinical investigation 2011; 41(5): 552-60.
15. Murai M, Baba S, Nakashima J, Tachibana M. Management of incidentally discovered adrenal masses. World journal of urology 1999; 17(1): 9-14.
16. Chiodini I, Vainicher CE, Morelli V, et al. MECHANISMS IN ENDOCRINOLOGY: Endogenous subclinical hypercortisolism and bone: a clinical review. European journal of
endocrinology 2016; 175(6): R265-R82.
17. Boronat M, Moreno A, Ramon y Cajal S, Pineda E, Lucas T, Estrada J. Subclinical Cushing's syndrome due to adrenal myelolipoma. Archives of pathology & laboratory medicine 1997; 121(7): 735-7.
18. Duan K, Hernandez KG, Mete O. Clinicopathological correlates of adrenal Cushing's syndrome. Journal of clinical pathology 2015; 68(3): 175-86.
19. Chiodini I. Clinical review: Diagnosis and treatment of subclinical hypercortisolism. The
Journal of clinical endocrinology and metabolism 2011; 96(5): 1223-36.
20. Bencsik Z, Szabolcs I, Goth M, et al. Incidentally detected adrenal tumours
(incidentalomas): histological heterogeneity and differentiated therapeutic approach. Journal
61 21. Barzon L, Scaroni C, Sonino N, et al. Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates. The Journal of clinical endocrinology and metabolism 1998; 83(1): 55-62.
22. Morelli V, Palmieri S, Lania A, et al. Cardiovascular events in patients with mild autonomous cortisol secretion: analysis with artificial neural networks. European journal of
endocrinology 2017; 177(1): 73-83.
23. Ioachimescu AG, Remer EM, Hamrahian AH. Adrenal incidentalomas: a disease of modern technology offering opportunities for improved patient care. Endocrinology and
metabolism clinics of North America 2015; 44(2): 335-54.
24. Terzolo M, Osella G, Ali A, et al. Subclinical Cushing's syndrome in adrenal incidentaloma. Clinical endocrinology 1998; 48(1): 89-97.
25. Terzolo M, Bovio S, Reimondo G, et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinology and metabolism clinics of North America 2005; 34(2): 423-39, x. 26. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. The Journal of laboratory and clinical medicine 1955; 45(1): 3-17.
27. Conn JW, Knopf RF, Nesbit RM. Clinical Characteristics of Primary Aldosteronism from an Analysis of 145 Cases. American journal of surgery 1964; 107: 159-72.
28. Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366(9486): 665-75.
29. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M. Risk factors and long- term follow-up of adrenal incidentalomas. The Journal of clinical endocrinology and
metabolism 1999; 84(2): 520-6.
30. Morelli V, Scillitani A, Arosio M, Chiodini I. Follow-up of patients with adrenal
incidentaloma, in accordance with the European society of endocrinology guidelines: Could we be safe? Journal of endocrinological investigation 2017; 40(3): 331-3.
31. Morelli V, Reimondo G, Giordano R, et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. The Journal of clinical endocrinology and
metabolism 2014; 99(3): 827-34.
32. Terzolo M, Pia A, Alì A, et al. Adrenal incidentaloma: A new cause of the metabolic syndrome? Journal of Clinical Endocrinology and Metabolism 2002; 87(3): 998-1003.
33. Tauchmanovà L, Rossi R, Biondi B, et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. Journal of Clinical Endocrinology
and Metabolism 2002; 87(11): 4872-8.
34. Iacobellis G, Petramala L, Barbaro G, et al. Epicardial fat thickness and left ventricular mass in subjects with adrenal incidentaloma. Endocrine 2013; 44(2): 532-6.
35. Morelli V, Eller-Vainicher C, Salcuni AS, et al. Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. Journal of bone and mineral research : the official journal of the American
Society for Bone and Mineral Research 2011; 26(8): 1816-21.
36. Terzolo M, Pia A, Reimondo G. Subclinical Cushing's syndrome: definition and management. Clinical endocrinology 2012; 76(1): 12-8.
37. Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. European journal of endocrinology 2011; 164(6): 851-70.
38. NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma"). NIH consensus and state-of-the-science statements 2002; 19(2): 1-25.
39. Di Dalmazi G, Vicennati V, Rinaldi E, et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. European journal of
62 40. Fernandez-Real JM, Engel WR, Simo R, Salinas I, Webb SM. Study of glucose tolerance in consecutive patients harbouring incidental adrenal tumours. Study Group of Incidental Adrenal Adenoma. Clinical endocrinology 1998; 49(1): 53-61.
41. Garrapa GG, Pantanetti P, Arnaldi G, Mantero F, Faloia E. Body composition and metabolic features in women with adrenal incidentaloma or Cushing's syndrome. The Journal
of clinical endocrinology and metabolism 2001; 86(11): 5301-6.
42. Ermetici F, Malavazos AE, Corbetta S, et al. Adipokine levels and cardiovascular risk in patients with adrenal incidentaloma. Metabolism: clinical and experimental 2007; 56(5): 686- 92.
43. Yener S, Genc S, Akinci B, et al. Carotid intima media thickness is increased and associated with morning cortisol in subjects with non-functioning adrenal incidentaloma.
Endocrine 2009; 35(3): 365-70.
44. Coiro V, Volpi R, Capretti L, et al. The nocturnal serum thyrotropin surge is inhibited in patients with adrenal incidentaloma. Journal of investigative medicine : the official publication
of the American Federation for Clinical Research 2002; 50(5): 350-4; discussion 4-5.
45. Siren J, Tervahartiala P, Sivula A, Haapiainen R. Natural course of adrenal incidentalomas: seven-year follow-up study. World J Surg 2000; 24(5): 579-82.
46. Reincke M. Subclinical Cushing's syndrome. Endocrinology and metabolism clinics of
North America 2000; 29(1): 43-56.
47. Angeli A, Terzolo M. Adrenal incidentaloma--a modern disease with old complications.
The Journal of clinical endocrinology and metabolism 2002; 87(11): 4869-71.
48. Chiodini I, Morelli V, Salcuni AS, et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. The
Journal of clinical endocrinology and metabolism 2010; 95(6): 2736-45.
49. Masserini B, Morelli V, Palmieri S, et al. Lipid abnormalities in patients with adrenal incidentalomas: role of subclinical hypercortisolism and impaired glucose metabolism. Journal
of endocrinological investigation 2015; 38(6): 623-8.
50. Isidori AM, Graziadio C, Paragliola RM, et al. The hypertension of Cushing's syndrome: controversies in the pathophysiology and focus on cardiovascular complications. Journal of
hypertension 2015; 33(1): 44-60.
51. Grasso M, Boscaro M, Scaroni C, Ceccato F. Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. High blood pressure &
cardiovascular prevention : the official journal of the Italian Society of Hypertension 2018;
25(4): 345-54.
52. Kastelan D, Kraljevic I, Dusek T, et al. The clinical course of patients with adrenal incidentaloma: is it time to reconsider the current recommendations? European journal of
endocrinology 2015; 173(2): 275-82.
53. Tuna MM, Imga NN, Dogan BA, et al. Non-functioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. Journal of
endocrinological investigation 2014; 37(8): 765-8.
54. Giordano R, Marinazzo E, Berardelli R, et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur J Endocrinol 2010; 162(4): 779-85.
55. Kim J, Bae KH, Choi YK, et al. Clinical characteristics for 348 patients with adrenal incidentaloma. Endocrinology and metabolism (Seoul, Korea) 2013; 28(1): 20-5.
56. Caoili EM, Korobkin M, Francis IR, Cohan RH, Dunnick NR. Delayed enhanced CT of lipid-poor adrenal adenomas. AJR American journal of roentgenology 2000; 175(5): 1411-5. 57. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR
American journal of roentgenology 2002; 179(3): 559-68.
58. Szolar DH, Korobkin M, Reittner P, et al. Adrenocortical carcinomas and adrenal pheochromocytomas: Mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 2005; 234(2): 479-85.
63 59. Young WF, Jr. Conventional imaging in adrenocortical carcinoma: update and
perspectives. Hormones & cancer 2011; 2(6): 341-7.
60. Pender SM, Boland GW, Lee MJ. The incidental nonhyperfunctioning adrenal mass: an imaging algorithm for characterization. Clinical radiology 1998; 53(11): 796-804.
61. Sahdev A, Reznek RH. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends in endocrinology and metabolism: TEM 2004; 15(6): 271-6.
62. Korobkin M, Francis IR, Kloos RT, Dunnick NR. The incidental adrenal mass. Radiologic
clinics of North America 1996; 34(5): 1037-54.
63. Korobkin M, Giordano TJ, Brodeur FJ, et al. Adrenal adenomas: relationship between histologic lipid and CT and MR findings. Radiology 1996; 200(3): 743-7.
64. Goddard GM, Ravikumar A, Levine AC. Adrenal mild hypercortisolism. Endocrinology
64
RINGRAZIAMENTI
Per la realizzazione di questa tesi di laurea ringrazio sentitamente il Prof. Massimo Tonacchera per i suoi insegnamenti e per la sua disponibilità.
Ringrazio la dott.ssa Francesca Orsolini, estremamente educata, disponibile e capace, per avermi seguita nella realizzazione di questo elaborato e avermi dato i giusti consigli, così come ringrazio anche il dott. Angelo Molinari per le sue conoscenze e i suggerimenti che mi ha dato. Un pensiero speciale è rivolto verso i miei genitori, nonché mio orgoglio, avendomi sempre accompagnato nei momenti importanti della vita.
Anche se non sarà mai abbastanza, voglio ringraziare:
mia madre per avermi ascoltata e incoraggiata nei momenti di ansia e preoccupazione, per aver
sempre trovato le giuste parole di conforto e motivazione e per aver creduto in me e nelle mie capacità;
e mio padre per essere sempre stato la mia colonna portante in tutti questi anni, come del resto continuerà ad esserlo, e per l’instancabile sostegno sia morale sia economico che mi ha permesso di arrivare fin qui, contribuendo alla mia formazione personale.
Altrettanto, un tenero pensiero è rivolto verso i miei nonni e zii che hanno sempre speso belle parole di incoraggiamento nei miei confronti.
A Marco, che con la sua spontaneità e leggerezza ha saputo supportarmi e “sopportarmi” durante tutti questi anni di studio. Molti sono i suoi pregi, ma tra i tanti, voglio riconoscergli il merito di avermi ascoltata e rincuorata nei miei momenti più difficili.
Un grazie di cuore, anche se uno solo non basta, alle mie amiche e compagne di corso Francesca, Arianna e Beatrice per esserci sempre state, anche nei momenti di sconforto. L’amicizia nata tra di noi in questi anni è stata una splendida scoperta. Senza di loro non sarebbe stata la stessa cosa; ci siamo sempre incoraggiate a vicenda come una “vera squadra”. Grazie alla loro costante e quotidiana presenza, ad oggi sono uno dei motivi principali per cui sono riuscita a portare a termine questo percorso di studi.
Infine, ma non certo per importanza, un ringraziamento speciale a tutti i miei amici che hanno preso parte alla mia vita in questi anni e che ha contribuito alla realizzazione di questo primo traguardo del mio percorso di vita.